FAAS
KERX

First Allied Advisory Services’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

First Allied Advisory Services’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,150
Closed -$171K – 1135
2014
Q2 		$171K Buy
+11,150
New +$158K 0.01% 903

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

First Allied Advisory Services's KERX Position: Q3 2014 in Review

First Allied Advisory Services sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2014, closing a stake of 11,150 shares — an estimated $171K sold.

First Allied Advisory Services first reported a position in KERX in Q2 2014 and held it in 1 quarter. The position peaked at $171K in Q2 2014. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • First Allied Advisory Services reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2014 after selling out during the quarter.
  • First Allied Advisory Services sold 11,150 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $171K.
  • First Allied Advisory Services first reported a position in Keryx Biopharmaceuticals Inc in Q2 2014 and held it in 1 quarter.
  • First Allied Advisory Services's Keryx Biopharmaceuticals Inc position peaked at $171K in Q2 2014.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on First Allied Advisory Services's 13F filing for Q3 2014, filed 12 Nov 2014.